Ticker Details
Nektar Therapeutics Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
IPO Date:	May 3, 1994
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$2.23B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.41 | 2.60%
Avg Daily Range (30 D):	$2.00 | 2.80%
Avg Daily Range (90 D):	$1.88 | 3.35%

Institutional Daily Volume
Avg Daily Volume:	1.44M
Avg Daily Volume (30 D):	.77M
Avg Daily Volume (90 D):	.92M

Trade Size
Avg Trade Size (Sh.):	161
Avg Trade Size (Sh.) (30 D):	62
Avg Trade Size (Sh.) (90 D):	64

Institutional Trades
Total Institutional Trades:	9,362
Avg Institutional Trade:	$2.69M
Avg Institutional Trade (30 D):	$3.43M
Avg Institutional Trade (90 D):	$2.5M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.85M
Avg Closing Trade (30 D):	$4.69M
Avg Closing Trade (90 D):	$3.62M
Avg Closing Volume:	18.59K

News

Apr 10, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Nektar The... Source: Bronstein, Gewirtz & Grossman Llc

Apr 8, 2026 @ 4:00 PM Deadline Alert: Nektar Therapeutics (NKTR) Shareho... Source: Glancy Prongay Wolke & Rotter Llp

Apr 7, 2026 @ 7:45 PM Pomerantz Law Firm Announces the Filing of a Class... Source: Pomerantz Llp

Apr 6, 2026 @ 10:35 PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nek... Source: Rosen Law Firm

Apr 6, 2026 @ 8:52 PM Holzer & Holzer, LLC Reminds Investors of Lead Pla... Source: Holzer & Holzer, Llc

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-9.73	$-1.59	$-9.73
Diluted EPS	$-9.73	$-1.59	$-9.73
Revenue	$55.23M	$21.81M	$55.23M
Gross Profit
Net Income / Loss	$-164.08M	$-36.08M	$-164.08M
Operating Income / Loss	$-140.1M	$-27.67M	$-140.1M
Cost of Revenue	$M	$M	$M
Net Cash Flow	$-29.14M	$-25.92M	$-29.14M
PE Ratio

Splits
Jun 09, 2025	1:15
Aug 23, 2000	2:1